The complexity of caring for patients with hematologic malignancies has increased dramatically. Over the last 5 years given new therapeutic approaches and treatment modalities. Hematopoietic stem cell therapy has also evolved and cell therapy is progressively becoming an all-encompassing term that includes the use of blood derived cells to treat cancer with, or without “classic” blood or marrow transplantation. Indications for transplant are also changing, reflecting better disease stage and risk stratification based upon newer technologies such as molecular or flow cytometry approaches.
The stem cell transplant program at University Hospitals Seidman Cancer Center continues to expand by offering treatments for a broad spectrum of diagnosis and disease stages. Clinical trials aimed at decreasing preparative regimen toxicity, reducing the likelihood of post-transplant relapse, and at using alternative donors are available.
This new app was developed by the American Society of Blood and Marrow Transplantation, the Center for international Bone Marrow Research and the National Marrow Donor Program.